Renin-angiotensin-system inhibitors and the risk of exacerbations in chronic obstructive pulmonary disease: a nationwide registry study

Frida Vilstrup, Christian Kjer Heerfordt, Peter Kamstrup, Caroline Hedsund, Tor Biering-Sørensen, Rikke Sørensen, Shailesh Kolekar, Ole Hilberg, Lars Pedersen, Thomas Kromann Lund, Tobias Wirenfeldt Klausen, Kristoffer Grundtvig Skaarup, Josefin Eklöf, Pradeesh Sivapalan, Jens Ulrik Stæhr Jensen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

8 Downloads (Pure)

Abstract

Objective The renin-angiotensin system (RAS) has been shown to play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD) because of the inflammatory properties of the system. Many patients with COPD use RAS-inhibiting (RASi) treatment. The aim was to determine the association between treatment with RASi and the risk of acute exacerbations and mortality in patients with severe COPD. Methods Active comparator analysis by propensity-score matching. Data were collected in Danish national registries, containing complete information on health data, prescriptions, hospital admissions and outpatient clinic visits. Patients with COPD (n=38 862) were matched by propensity score on known predictors of the outcome. One group was exposed to RASi treatment (cases) and the other was exposed to bendroflumethiazide as an active comparator in the primary analysis. Results The use of RASi was associated with a reduced risk of exacerbations or death in the active comparator analysis at 12 months follow-up (HR 0.86, 95% CI 0.78 to 0.95). Similar results were evident in a sensitivity analysis of the propensity-score-matched population (HR 0.89, 95% CI 0.83 to 0.94) and in an adjusted Cox proportional hazards model (HR 0.93, 95% CI 0.89 to 0.98). Conclusion In the current study, we found that the use of RASi treatment was associated with a consistently lower risk of acute exacerbations and death in patients with COPD. Explanations to these findings include real effect, uncontrolled biases, and - less likely - chance findings.

Original languageEnglish
Article numbere001428
JournalBMJ Open Respiratory Research
Volume10
Issue number1
Number of pages8
ISSN2052-4439
DOIs
Publication statusPublished - 7. Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 Author(s). Published by BMJ.

Keywords

  • COPD epidemiology
  • COPD Exacerbations
  • COPD Pathology
  • COPD Pharmacology

Fingerprint

Dive into the research topics of 'Renin-angiotensin-system inhibitors and the risk of exacerbations in chronic obstructive pulmonary disease: a nationwide registry study'. Together they form a unique fingerprint.

Cite this